SCHEMBL2433396

SCHEMBL2433396

CCOC(=O)C1(COc2ccc(-c3ccc(C#N)cc3)cc2)CCN(C(=O)c2ccc(F)cc2)C1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER2 P43116 3/20 0.67
PTGER4 P35408 1/20 0.67
PTGDR Q13258 1/20 0.67
DRD1 P21728 1/20 0.48
HRH4 Q9H3N8 1/20 0.48
HRH2 P25021 2/20 0.47
HRH1 P35367 2/20 0.47
HRH3 Q9Y5N1 1/20 0.47
NQO2 P16083 1/20 0.46
PDE3B Q13370 1/20 0.46
PDE3A Q14432 1/20 0.46
LTB4R Q15722 1/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.46
CYP3A4 P08684 3/20 0.44
CYP2D6 P10635 1/20 0.44
GAA P10253 1/20 0.43
TACR3 P29371 2/20 0.43
USP2 O75604 3/20 0.43
TSHR P16473 3/20 0.43
CYP2C9 P11712 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2433795 0.94 PTGER2 (0.56) PTGER2PTGER4PTGDRDRD1HRH4
SCHEMBL2435176 0.92 PTGER4 (0.80) PTGER2PTGER4PTGDRHRH2HRH1
SCHEMBL2437151 0.92 PTGER4 (0.68) PTGER2PTGER4PTGDRHRH2HRH1
SCHEMBL2434921 0.90 PTGER2 (0.62) PTGER2PTGER4PTGDRDRD1HRH4
SCHEMBL2440236 0.90 PTGER2 (0.53) PTGER2PTGER4PTGDRDRD1HRH4
SCHEMBL2435853 0.88 PTGER2 (0.82) PTGER2PTGER4PTGDRDRD1HRH4
SCHEMBL2438543 0.85 PTGER2 (0.48) PTGER2PTGER4PTGDRDRD1HRH4
SCHEMBL2438797 0.83 PTGER4 (0.59) PTGER2PTGER4PTGDRHRH2HRH1
SCHEMBL2432590 0.83 PTGER2 (0.43) PTGER2PTGER4PTGDRDRD1HRH4
SCHEMBL2441662 0.83 PTGER2 (0.46) PTGER2PTGER4PTGDRDRD1HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278343-B2 Pyrrolidines PFIZER INC. (US) 2012-10-02 US disclosed
US-8278343-B2 Pyrrolidines PFIZER INC. (US) 2012-10-02 US disclosed
US-8278343-B2 Pyrrolidines PFIZER INC. (US) 2012-10-02 US disclosed
EP-2364296-A1 PYRROLIDINES Pfizer Limited (GB) 2011-09-14 EP disclosed
WO-2010052625-A1 PYRROLIDINES PFIZER LIMITED (GB) 2010-05-14 WO disclosed
WO-2010052625-A1 PYRROLIDINES PFIZER LIMITED (GB) 2010-05-14 WO disclosed
US-20100120793-A1 Pyrrolidines PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) 2010-05-13 US disclosed
US-20100120793-A1 Pyrrolidines PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) 2010-05-13 US disclosed
US-20100120793-A1 Pyrrolidines PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120793-A1 Pyrrolidines PTGER2, PTGDR2, PTGES2 PTGER2 1/4885PTGER4 11/4885PTGDR 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.